慢性阻塞性肺疾病和肺心病患者血浆TXB_2、6-Keto-PGF_(1a)的测定  

Measurements of Plasma TXB_2,6-Keto-PGF_(1a) in Chronic Obstructive Pulmonary Disease(COPD)and Pulmonary Heart Diseases.

作　　者：刘韵蝉[1] 唐筑灵[1] 何燕[1] 

机构地区：[1]贵阳医学院附院内科,贵州贵阳550004

出　　处：《贵阳医学院学报》2002年第4期314-315,共2页Journal of Guiyang Medical College

摘　　要：目的 :探讨慢性阻塞性肺疾病 (COPD)和肺心病患者血浆血栓素 (TXB2 )和 6 -酮 -前列环素F1a(6 -Keto -PGF1a)的变化及临床意义。方法 :采用放射免疫法测定血浆TXB2 、6 -Keto -PGF1a的浓度。结果 :COPD患者血浆TXB2 与对照组比较无明显差异 (P >0 0 5 )。肺心病急性发作期TXB2 明显高于对照组及COPD组 ,差异有显著性 (P <0 0 1)。COPD组及肺心病组 6 -Keto -PGF1a与对照组比较差异有显著性 (P <0 0 1)。结论 :TXB2 在肺心病肺动脉高压的发生发展中起着重要的作用。Objective: To investigate the changes of TXB 2 and 6-Keto-PGF 1a in patients of COPD and pulmonary heart disease.Methods:The radioimmunoassay (RIA) were used to measure levels of plasma TXB 2 and 6-Keto-PGF 1a.Results:Level of plasma TXB 2 in COPD was similar to that of control's (P>0 05).The plasma TXB 2 in pulmonary heart disease patients were higer than those of control's and COPD(P<0 01).the plasma 6-Keto-PGF 1a in COPD and pulmonary heart disease groups were higher than that of control's (P<0 01).Conclusion:The results of this study suggest that TXB 2 have an important effect in the development of high pulmonary arterial Pressure in pulmonary heart disease.

关 键 词：阻塞性肺疾病 肺心病 血栓烷B2 合成前列腺素类 血浆 

分 类 号：R563[医药卫生—呼吸系统] R541.5[医药卫生—内科学]